Grifols (GRFS)
(Delayed Data from NSDQ)
$8.84 USD
+0.01 (0.11%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $8.84 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.84 USD
+0.01 (0.11%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $8.84 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth F Momentum D VGM
Zacks News
Amgen Files for Xgeva Label Expansion, To Include Myeloma
by Zacks Equity Research
Amgen, Inc. (AMGN) recently announced that it has submitted a supplemental Biologics License Application (sBLA) to the FDA to expand the label of its key drug, Xgeva.
Sanofi's (SNY) Diabetes Drug Toujeo Lowers Hypoglycemia Risk
by Zacks Equity Research
A real-world observational study showed that when type 2 diabetes patients on basal insulin switched to Toujeo, it led to a significant reduction in risk of hypoglycemia without compromising blood sugar control
AbbVie's (ABBV) Humira Drug Label Update Approved by FDA
by Zacks Equity Research
AbbVie Inc.'s (ABBV) announced that the FDA has approved the inclusion of moderate to severe fingernail psoriasis data on the label of AbbVie???s multi-utility TNF blocker drug, Humira
New Strong Buy Stocks for March 30th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
Catalyst Pharmaceuticals (CPRX) Jumps: Stock Gains 18.2%
by Zacks Equity Research
Catalyst Pharmaceuticals, Inc. (CPRX) moved big last session, as its shares rose over 18% on the day.
5 Cheap PEG Picks for Value Investors Right Now
by Zacks Equity Research
PEG is the ratio with the earnings growth component in it.
Allergan's Dermal Filler for Wrinkle Correction Gets FDA Nod
by Zacks Equity Research
Allergan plc (AGN) announced yesterday that the FDA has approved its Juvederm Vollure XC dermal filler for correction of facial wrinkles and folds in adults over the age of 21.
AstraZeneca (AZN) Gets Another CRL for ZS-9; Inks COPD Deal
by Zacks Equity Research
London based AstraZeneca plc (AZN) received a second Complete Response Letter (CRL) from the FDA for its new drug application (NDA) for investigational drug ZS-9.
Is Grifols a Great Stock for Value Investors?
by Zacks Equity Research
Let's focus on Grifols, S.A. (GRFS) stock and find out if it is a good choice for value-oriented investors right now or not.
Aurinia (AUPH) Catches Eye: Stock Moves up 8.5% in Session
by Zacks Equity Research
Aurinia Pharmaceuticals Inc. (AUPH) moved big last session, as its shares rose above 8% on the day.
Esperion Therapeutics (ESPR) Jumps: Stock Moves Up 8.6%
by Zacks Equity Research
Esperion Therapeutics, Inc. (ESPR) moved big last session, as its shares rose above 8% on the day.
New Strong Buy Stocks for March 9th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
Infinity Pharmaceuticals (INFI) Catches Eye: Stock Up 13.5%
by Zacks Equity Research
Infinity Pharmaceuticals, Inc. (INFI) saw its shares rise almost 7% in the last trading session.
Hologic (HOLX) to Divest Blood Screening Business to Grifols
by Zacks Equity Research
Hologic, Inc. (HOLX) recently inked a deal to divest its stake in the blood screening business.
The Power of New Analyst Coverage
by Kevin Matras
Kevin Matras shows why stocks with new analyst coverage are stocks you want to have. Highlighted stocks include GRFS, PRGN, GWRE, ABM and THG.